Trius Therapeutics plans to price public offering of its common stock

Deal to be conducted by joint bookrunners Citigroup and Leerink Swann

By Toni Weeks

San Diego, Jan. 17 - Trius Therapeutics, Inc. said it will conduct a public offering of its common stock with a 30-day greenshoe.

Citigroup Global Markets Inc. and Leerink Swann LLC are the joint bookrunning managers, with Robert W. Baird & Co. Inc. as co-lead manager.

Proceeds will be used for general corporate purposes, including clinical trial, pre-clinical development and other research and development expenses, capital expenditures, working capital, administrative expenses and potential acquisitions of or investments in complementary businesses, products and technologies.

Trius will also offer shares of its common stock in a concurrent offering under a 2011 registration statement, the filing noted.

Based in San Diego, Trius is a biopharmaceutical company focused on the discovery, development and commercialization of antibiotics for life-threatening infections.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.